Skip to main content
Erschienen in: Annals of Nuclear Medicine 4/2022

27.01.2022 | Original Article

Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer

verfasst von: Aiqi Shi, Jianling Wang, Yuzhu Wang, Guorong Guo, Chouchou Fan, Jiangyan Liu

Erschienen in: Annals of Nuclear Medicine | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To explore the value of multiple metabolic and heterogeneity parameters of 2-deoxy-2-[fluorine-18] fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting epidermal growth factor receptor gene (EGFR) mutations in non-small cell lung cancer (NSCLC).

Materials and methods

A retrospective analysis was performed by reviewing 98 patients with NSCLC who underwent EGFR mutation testing and 18F-FDG PET/CT examination in our hospital between March 2016 and March 2021. Patients were divided into an EGFR-mutant group and a wild-type group. A multivariate logistic regression analysis was performed to screen and construct a prediction model. The diagnostic performance of the model was evaluated using a receiver-operating characteristic (ROC) curve.

Results

The study found that EGFR mutations were more likely to occur in women, non-smokers, and patients with peripheral lesions, shorter maximum tumor diameter, adenocarcinoma, and T1 stage cancer. Low maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume, total lesion glycolysis, and high coefficient of variation (COV) were significantly correlated with EGFR mutations, and the area under the ROC curve (AUC) was 0.622, 0.638, 0.679, 0.687, and 0.672, respectively. Multivariate logistic regression analysis indicated that non-smokers (odds ratio (OR) = 0.109, P = 0.014), peripheral lesions (OR = 6.917, P = 0.022), low SUVmax (≤ 7.85, OR = 5.471, P = 0.001), SUVmean (≤ 5.34, OR = 0.044, P = 0.000), and high COV (≥ 106.08, OR = 0.996, P = 0.045) were independent predictors of EGFR mutations. The AUC of the prediction model established by combining the above factors was 0.926; the diagnostic efficiency was significantly higher than that of a single parameter.

Conclusion

Among the metabolic and heterogeneity parameters of 18F-FDG PET/CT, low SUVmax, SUVmean, and high COV were significantly associated with EGFR mutations, and the predictive value of EGFR mutations could be enhanced when combined with clinicopathological features.
Literatur
1.
Zurück zum Zitat Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4): 313. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70(4): 313.
2.
Zurück zum Zitat Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, et al. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest. 2020;130(2):612–24.CrossRef Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, et al. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest. 2020;130(2):612–24.CrossRef
3.
Zurück zum Zitat An N, Zhang Y, Niu H, Li Z, Cai J, Zhao Q, et al. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine. 2016;95(50):e5601.CrossRef An N, Zhang Y, Niu H, Li Z, Cai J, Zhao Q, et al. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine. 2016;95(50):e5601.CrossRef
4.
Zurück zum Zitat McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–28.CrossRef McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–28.CrossRef
5.
Zurück zum Zitat Van Baardwijk A, Bosmans G, van Suylen RJ, van Kroonenburgh M, Hochstenbag M, Geskes G, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87(1):55–8.CrossRef Van Baardwijk A, Bosmans G, van Suylen RJ, van Kroonenburgh M, Hochstenbag M, Geskes G, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87(1):55–8.CrossRef
6.
Zurück zum Zitat Moon SH, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, et al. Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. Br J Radiol. 2016;89(1067):20160109.CrossRef Moon SH, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, et al. Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. Br J Radiol. 2016;89(1067):20160109.CrossRef
7.
Zurück zum Zitat Pahk K, Chung JH, Yi E, Kim S, Lee SH. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2. Eur J Radiol. 2018;106:145–9.CrossRef Pahk K, Chung JH, Yi E, Kim S, Lee SH. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2. Eur J Radiol. 2018;106:145–9.CrossRef
8.
Zurück zum Zitat Yoon HJ, Kim Y, Kim BS. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. Eur Radiol. 2015;25(12):3648–58.CrossRef Yoon HJ, Kim Y, Kim BS. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. Eur Radiol. 2015;25(12):3648–58.CrossRef
9.
Zurück zum Zitat Watabe T, Tatsumi M, Watabe H, Isohashi K, Kato H, Yanagawa M, et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26(3):222–7.CrossRef Watabe T, Tatsumi M, Watabe H, Isohashi K, Kato H, Yanagawa M, et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26(3):222–7.CrossRef
10.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the Forthcoming (Eighth) Edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRef Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the Forthcoming (Eighth) Edition of the TNM Classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.CrossRef
11.
Zurück zum Zitat Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer. 2014;83(2):197–204.CrossRef Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer. 2014;83(2):197–204.CrossRef
12.
Zurück zum Zitat Na II, Byun BH, Kim KM, Cheon GJ, Choe DH, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80.CrossRef Na II, Byun BH, Kim KM, Cheon GJ, Choe DH, Koh JS, et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer. 2010;67(1):76–80.CrossRef
13.
Zurück zum Zitat Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine. 2016;95(30):e4421.CrossRef Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, et al. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. Medicine. 2016;95(30):e4421.CrossRef
14.
Zurück zum Zitat Gu J, Xu S, Huang L, Wu J, Xu J, Feng J, et al. Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. J Thorac Dis. 2018;10(2):723–31.CrossRef Gu J, Xu S, Huang L, Wu J, Xu J, Feng J, et al. Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. J Thorac Dis. 2018;10(2):723–31.CrossRef
15.
Zurück zum Zitat Hong IK, Lee JM, Hwang IK, Paik SS, Kim C, Lee SH, et al. Diagnostic and predictive values of 18F-FDG PET/CT metabolic parameters in EGFR-mutated advanced lung adenocarcinoma. Cancer Manag Res. 2020;12:6453–65.CrossRef Hong IK, Lee JM, Hwang IK, Paik SS, Kim C, Lee SH, et al. Diagnostic and predictive values of 18F-FDG PET/CT metabolic parameters in EGFR-mutated advanced lung adenocarcinoma. Cancer Manag Res. 2020;12:6453–65.CrossRef
16.
Zurück zum Zitat Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2019;15(6):637–52.CrossRef Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2019;15(6):637–52.CrossRef
17.
Zurück zum Zitat Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol. 2019;54(1):370–80.PubMed Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol. 2019;54(1):370–80.PubMed
18.
Zurück zum Zitat Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010;27(1):9–15.CrossRef Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2010;27(1):9–15.CrossRef
19.
Zurück zum Zitat Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging. 2014;41(10):1889–97.CrossRef Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging. 2014;41(10):1889–97.CrossRef
20.
Zurück zum Zitat Wang Y, Han R, Wang Q, Zheng J, Lin C, Lu C, et al. Biological significance of 18F-FDG PET/CT maximum standard uptake value for predicting EGFR mutation status in non-small cell lung cancer patients. Int J Gen Med. 2021;14:347–56.CrossRef Wang Y, Han R, Wang Q, Zheng J, Lin C, Lu C, et al. Biological significance of 18F-FDG PET/CT maximum standard uptake value for predicting EGFR mutation status in non-small cell lung cancer patients. Int J Gen Med. 2021;14:347–56.CrossRef
21.
Zurück zum Zitat Lee SM, Bae SK, Jung SJ, Kim CK. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Clin Nucl Med. 2015;40(12):950–8.CrossRef Lee SM, Bae SK, Jung SJ, Kim CK. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Clin Nucl Med. 2015;40(12):950–8.CrossRef
22.
Zurück zum Zitat Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Oncotarget. 2017;8(32):52792–801.CrossRef Minamimoto R, Jamali M, Gevaert O, Echegaray S, Khuong A, Hoang CD, et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Oncotarget. 2017;8(32):52792–801.CrossRef
23.
Zurück zum Zitat Kim YI, Paeng JC, Park YS, Cheon GJ, Lee DS, Chung JK, et al. Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the Use of FDG PET/CT parameters in prognosis. Am J Roentgenol. 2018;210(6):1346–51.CrossRef Kim YI, Paeng JC, Park YS, Cheon GJ, Lee DS, Chung JK, et al. Relation of EGFR mutation status to metabolic activity in localized lung adenocarcinoma and its influence on the Use of FDG PET/CT parameters in prognosis. Am J Roentgenol. 2018;210(6):1346–51.CrossRef
24.
Zurück zum Zitat Whi W, Ha S, Bae S, Choi H, Paeng JC, Cheon GJ, et al. Relationship of EGFR mutation to glucose metabolic activity and asphericity of metabolic tumor volume in lung adenocarcinoma. Nucl Med Mol Imaging. 2020;54(4):175–82.CrossRef Whi W, Ha S, Bae S, Choi H, Paeng JC, Cheon GJ, et al. Relationship of EGFR mutation to glucose metabolic activity and asphericity of metabolic tumor volume in lung adenocarcinoma. Nucl Med Mol Imaging. 2020;54(4):175–82.CrossRef
25.
Zurück zum Zitat Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium. Cancer. 2016;122(5):766–72.CrossRef Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, et al. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: results from the Lung Cancer Mutation Consortium. Cancer. 2016;122(5):766–72.CrossRef
26.
Zurück zum Zitat Zhu L, Yin G, Chen W, Li X, Yu X, Zhu X, et al. Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. Thorac Cancer. 2019;10(4):659–64.CrossRef Zhu L, Yin G, Chen W, Li X, Yu X, Zhu X, et al. Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma. Thorac Cancer. 2019;10(4):659–64.CrossRef
27.
Zurück zum Zitat Guo Y, Zhu H, Yao Z, Liu F, Yang D. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: a meta-analysis. Eur J Radiol. 2021;141:109792.CrossRef Guo Y, Zhu H, Yao Z, Liu F, Yang D. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: a meta-analysis. Eur J Radiol. 2021;141:109792.CrossRef
28.
Zurück zum Zitat Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, et al. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Oncotarget. 2017;8(20):33736–44.CrossRef Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, et al. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Oncotarget. 2017;8(20):33736–44.CrossRef
29.
Zurück zum Zitat Hong SJ, Kim TJ, Choi YW, Park JS, Chung JH, Lee KW. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes. Eur Radiol. 2016;26(10):3660–8.CrossRef Hong SJ, Kim TJ, Choi YW, Park JS, Chung JH, Lee KW. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes. Eur Radiol. 2016;26(10):3660–8.CrossRef
30.
Zurück zum Zitat Sugano M, Shimizu K, Nakano T, Kakegawa S, Miyamae Y, et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep. 2011;26(5):1205–11.PubMed Sugano M, Shimizu K, Nakano T, Kakegawa S, Miyamae Y, et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. Oncol Rep. 2011;26(5):1205–11.PubMed
Metadaten
Titel
Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer
verfasst von
Aiqi Shi
Jianling Wang
Yuzhu Wang
Guorong Guo
Chouchou Fan
Jiangyan Liu
Publikationsdatum
27.01.2022
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 4/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01718-8

Weitere Artikel der Ausgabe 4/2022

Annals of Nuclear Medicine 4/2022 Zur Ausgabe